Loading
ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.
ImmVira Pharma appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 1/2, 2), testing Herpes Virus C5252, T3011 in glioma, malignant, nonmuscle-invasive bladder cancer, solid tumor, melanoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.